Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that it is a drug with a manageable safety profile and promising antitumour activity, especially in patients with metastatic cutaneous melanoma refractory to immunotherapy with anti-PD1 immune checkpoint inhibitors.
ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
First MYC inhibitor to demonstrate safety and anti-tumor activity in a phase I first-in-human clinical trial medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
VHIO Develops VIGex: Pan-Cancer Platform for Personalized Immunotherapy miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.